FDA enforcement on non-approved compounded GLP-1s (2026)

On February 6, 2026, FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs that are mass-marketed as similar alternatives to approved drugs, naming Hims & Hers and other compounding pharmacies.[1]

What FDA said

FDA said companies cannot claim that non-approved compounded products are generic versions of, or the same as, FDA-approved drugs, cannot say they use the same active ingredient, and cannot say they are clinically proven to produce results. It warned that failing to address violations may lead to legal action without further notice, including seizure and injunction.[1]

Telehealth warning letters

On March 3, 2026, FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. The main problems it identified were claims implying sameness with approved products and branding that obscured who the compounder was. FDA described this as the second group of telehealth letters since a crackdown on misleading direct-to-consumer drug advertising began in September 2025.[2]

Compounded is not approved

FDA states that compounded drugs are not FDA approved, that it does not review their safety, effectiveness, or quality before marketing, and that they are not the same as generic drugs.[2][3]

Quality problems in one pharmacy

A January 2026 warning letter to Boothwyn Pharmacy described insanitary conditions for products intended to be sterile and drugs released with strengths that differed from their labels. FDA also noted that the firm had stopped producing sterile GLP-1 drug products and later told FDA it intended to resume.[4]

What this means for patients

None of these documents tell an individual patient to stop a prescribed medication. Questions about a specific prescription belong with the prescriber and dispensing pharmacy.

References

U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. Statement, February 6, 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs. Checked October 15, 2026.
U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press announcement, March 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s. Checked October 15, 2026.
U.S. Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. Content current as of June 15, 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs. Checked October 15, 2026.
U.S. Food and Drug Administration. Warning Letter to Boothwyn Pharmacy, LLC (MARCS-CMS 717525), January 16, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boothwyn-pharmacy-llc-717525-01162026. Checked October 15, 2026.

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend starting, stopping, or changing any medication.